# 10 Reasons Home Care Agency Sales Fall Through (And How to Prevent Each One) > Roughly one in three signed LOIs in home care M&A never reaches close. Here are the 10 most common deal killers — and the specific seller-side actions that prevent each one. Source: https://www.hendonpartners.com/insights/why-home-care-agency-sales-fall-through Author: Neli Gertner Published: 2026-05-04 Category: Seller Guides Tags: sell, due-diligence, M&A, home-care, deal-killers ---A signed Letter of Intent feels like the finish line. It is not. Across the home care M&A market, **roughly one in three signed LOIs never reaches close**. The reasons are remarkably consistent, repeating across personal care, home health, hospice, IDD, behavioral health, and pediatric agencies year after year. The good news: nearly every deal killer on this list is preventable with the right preparation. Below are the 10 most common reasons home care agency sales fall through — and the specific seller-side actions that prevent each one. --- ## 1. EBITDA Restatement During Quality of Earnings **What happens:** The buyer's QoE accountants review the financials in detail and produce a normalized EBITDA materially lower than the figure the LOI was based on. The buyer either retrades the purchase price downward, expands the earnout to bridge the gap, or walks. **Why it kills deals:** A 10% EBITDA reduction at a 7x multiple equals a 70% reduction in the proceeds gap that needs to be bridged. Sellers often refuse to accept the retrade, and buyers refuse to honor the original number. The deal stalemates and dies. **Prevention:** - Commission a **sell-side Quality of Earnings** report before market launch - Document every add-back with primary-source evidence - Reconcile QuickBooks to tax returns to bank statements before any buyer sees financials - Avoid aggressive normalization (rent below market, owner comp adjustments without market data) --- ## 2. Compliance and Licensing Surprises **What happens:** The buyer's healthcare regulatory counsel discovers an unresolved survey deficiency, an open OIG matter, a lapsed state license in a satellite office, an unresolved Medicare audit, or a pattern of HHCAHPS scores below threshold. **Why it kills deals:** Regulatory exposure transfers with the agency in most deal structures. Buyers — especially private equity platforms with lender covenants — cannot accept open compliance risk. Curing the issue often takes longer than the buyer's investment timeline allows. **Prevention:** - Run a **pre-sale compliance audit** with healthcare regulatory counsel 6–12 months ahead of process launch - Resolve all open survey citations, OIG inquiries, and licensure issues before going to market - Disclose remaining items proactively in the CIM with remediation plans - Maintain a current compliance log accessible in the data room from day one --- ## 3. Revenue and Referral Concentration **What happens:** Diligence reveals that 30%+ of revenue comes from a single payer, a single referral source, a single facility partnership, or a single geographic market. The buyer's investment committee flags concentration risk and either reprices, restructures with a concentration earnout, or declines to proceed. **Why it kills deals:** Concentration represents single-point-of-failure risk that institutional buyers are structurally unable to underwrite at full multiples. **Prevention:** - Quantify and disclose concentration in the CIM upfront — surprises kill, transparency negotiates - Show diversification trend lines (concentration declining year over year is a positive story) - Document the depth and resilience of concentrated relationships (length, contracts, succession of contacts) - If concentration is severe, consider 12–24 months of pre-sale diversification before launch --- ## 4. Caregiver Turnover and Workforce Issues **What happens:** The buyer's operational diligence identifies caregiver turnover rates above industry benchmark (typically >65–80% annual), an open labor dispute, a recent walkout, or active union organizing. In some markets, the buyer also flags undocumented worker exposure or wage-and-hour irregularities. **Why it kills deals:** Workforce instability directly reduces achievable EBITDA multiples. In severe cases, it suggests the post-close business may not deliver the historical financials buyers underwrote. **Prevention:** - Track and report caregiver turnover monthly in a defensible format - Resolve wage-and-hour exposure with employment counsel before going to market - Document caregiver retention initiatives (referral bonuses, training programs, recognition) - Address I-9 compliance proactively across all locations --- ## 5. Working Capital Disputes **What happens:** The buyer's working capital target ("peg") comes in materially higher than the seller expected, effectively reducing net proceeds at close by hundreds of thousands — sometimes millions — of dollars. Negotiations stall over the calculation methodology. **Why it kills deals:** Working capital is one of the most technically complex and most commonly mishandled areas of home care M&A. A peg dispute that surfaces late in the process consumes negotiating goodwill that the deal needs for closing. **Prevention:** - Build a **12-month trailing working capital analysis** before LOI - Negotiate the peg mechanism (TTM average vs. 6-month average vs. seasonally adjusted) explicitly in the LOI, not the purchase agreement - Aggressively manage A/R aging in the months leading to close - Engage M&A counsel and your advisor to model the peg outcome before signing exclusivity --- ## 6. Buyer Financing Falls Through **What happens:** The buyer — frequently a private equity platform — cannot secure the senior debt or unitranche financing on the terms assumed in the LOI. Lender appetite for home care has tightened (after the 80/20 rule, after a referral source change, after an interest rate cycle). The buyer asks for a price reduction or extends the timeline indefinitely. **Why it kills deals:** Time is the enemy of every M&A transaction. A financing delay introduces every other deal-killer risk: financial deterioration, key employee departure, market change, seller fatigue. **Prevention:** - Prioritize buyers with demonstrable **closing track records** in the past 12 months - Require the LOI to disclose financing structure and lender relationships - Run a competitive process so a financing failure with one buyer does not end the deal - Engage your advisor to vet the buyer's recent close certainty before granting exclusivity --- ## 7. Performance Decline During Diligence **What happens:** The agency's revenue, census, or EBITDA softens between LOI and close. A referral source slows, a facility contract is not renewed, a clinical leader departs, hours-per-week drops. The buyer either retrades to the new run-rate or walks. **Why it kills deals:** The buyer underwrote the LOI to historical performance. A 5–10% decline in the trailing 90 days is enough to trigger a meaningful retrade. Owners distracted by the deal often accelerate this decline by taking their eye off the operating business. **Prevention:** - Maintain operational discipline through close — the deal is not done until wires clear - Delegate as much diligence response as possible to your advisor and CFO - Build a 90-day "stay strong" plan with operations leadership before market launch - Communicate transparently with the buyer about any operating headwind early --- ## 8. CHOW and Regulatory Approval Timing **What happens:** Change of Ownership applications for Medicare, Medicaid, or state licenses take longer than expected. In some states, CHOW timelines stretch past 6 months. The buyer's exclusivity expires, financing commitments lapse, or the seller's patience runs out. **Why it kills deals:** Long CHOW timelines convert to extended risk windows. Either party may exit before the regulatory approval lands. **Prevention:** - File CHOW applications as early as possible after LOI execution - Map state-by-state CHOW timing into the deal calendar before signing - For multi-state agencies, identify the longest-pole state and structure close mechanics around it - Consider interim management agreements where state law permits --- ## 9. Buyer-Seller Fit Breakdown **What happens:** Cultural and operational misalignment surfaces during diligence. The buyer's post-close plan diverges sharply from what the seller understood at LOI — major staff reductions, branch closures, payer mix shifts, or rebranding. The seller, particularly when rolling equity or staying on through transition, decides not to proceed. **Why it kills deals:** First-time sellers often underweight the post-close vision question at LOI. By diligence, when the divergence becomes concrete, the relationship has already deteriorated. **Prevention:** - Vet buyers on **post-close operating philosophy** during management presentations, not after LOI - Speak with founders of agencies the buyer has previously acquired - Document the agreed post-close vision in the LOI where possible - Match buyer type to seller goals: a strategic full-exit looks very different from a PE majority recap with rollover --- ## 10. Seller Cold Feet **What happens:** The seller, often a founder, decides emotionally during diligence that they are not ready to sell. The volume and intensity of diligence requests, the realization that the business they built will be transferred, or a personal life event triggers withdrawal. **Why it kills deals:** Even when the deal terms are excellent, a seller who is not psychologically prepared can collapse a process at any point — and the legal and reputational cost is significant. **Prevention:** - Spend serious time on **the personal "why"** before engaging an advisor - Talk with peers who have completed sales — both those satisfied and unsatisfied with their outcomes - Model your post-close life: financial, professional, and personal - Engage a wealth advisor in parallel with M&A advisory so post-close clarity exists before close --- ## The Common Thread: Preparation Before Process Nine of these ten deal killers are addressable months before market launch. The single most reliable predictor of whether a home care agency sale closes is not the buyer, the multiple, or the market — it is **how prepared the seller was before the first buyer was contacted**. Sellers who run their process with a specialized advisor, with sell-side QoE in hand, with compliance pre-audited, with working capital modeled, with caregiver metrics defensible, and with a clear post-close vision close their deals at materially higher rates — and at materially better terms when they do. **[Talk to Hendon Partners about a confidential pre-sale assessment →](/contact-us)** --- *Hendon Partners is a sell-side only home care M&A advisory firm specializing in mid-sized, first-time sellers. We have advised on 150+ home-based care transactions across personal care, home health, hospice, IDD, behavioral health, and pediatric home health.* --- ## Frequently Asked Questions ### How often do home care agency sales fall through? Industry data and Hendon Partners' transaction history suggest that roughly 25–35% of signed Letters of Intent in home care M&A never reach close. The failure rate is significantly higher for unrepresented sellers and for first-time sellers without specialized M&A counsel. ### What is the most common reason a home care agency sale falls apart? EBITDA restatement during Quality of Earnings is the single most common deal killer. When the buyer's QoE team produces a normalized EBITDA materially lower than the seller's view, the buyer either retrades the price, restructures the deal with a larger earnout, or walks away. ### Can a home care agency sale fall through after signing the LOI? Yes. The LOI is non-binding (other than exclusivity and confidentiality clauses). The buyer can withdraw at any point during due diligence — and frequently does when financial, compliance, or operational issues surface. This is why seller-side preparation before the LOI is the most important protection against deal failure. ### What can a seller do to prevent a home care deal from collapsing? The three highest-impact prevention steps are: (1) sell-side Quality of Earnings before market launch to defend EBITDA, (2) a healthcare regulatory and compliance audit to surface and remediate issues 6–12 months ahead of sale, and (3) running a competitive process so any single buyer's withdrawal does not end the transaction.